Kyverna Therapeutics (NASDAQ:KYTX) Price Target Raised to $20.00 at HC Wainwright

Kyverna Therapeutics (NASDAQ:KYTX) had its target price boosted by HC Wainwright from $10.00 to $20.00 in a report released on Monday, Marketbeat Ratings reports. HC Wainwright currently has a buy rating on the stock.

KYTX has been the subject of several other research reports. William Blair began coverage on shares of Kyverna Therapeutics in a research report on Wednesday, August 20th. They issued an “outperform” rating for the company. Wells Fargo & Company raised their price target on shares of Kyverna Therapeutics from $24.00 to $27.00 and gave the company an “overweight” rating in a research report on Wednesday, October 8th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Kyverna Therapeutics in a research report on Tuesday, October 14th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $22.33.

Kyverna Therapeutics Stock Performance

NASDAQ:KYTX opened at $7.81 on Monday. The stock has a market capitalization of $337.78 million, a P/E ratio of -2.12 and a beta of 3.72. The company has a 50 day moving average price of $5.31 and a 200 day moving average price of $3.75. Kyverna Therapeutics has a fifty-two week low of $1.78 and a fifty-two week high of $8.45.

Kyverna Therapeutics (NASDAQ:KYTX) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.97) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.03. Research analysts forecast that Kyverna Therapeutics will post -3.29 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Kyverna Therapeutics

Several institutional investors have recently modified their holdings of the company. Insight Holdings Group LLC lifted its position in shares of Kyverna Therapeutics by 8.3% during the 1st quarter. Insight Holdings Group LLC now owns 989,054 shares of the company’s stock worth $1,909,000 after purchasing an additional 76,139 shares during the last quarter. Kera Capital Partners Inc. lifted its position in shares of Kyverna Therapeutics by 12.2% during the 2nd quarter. Kera Capital Partners Inc. now owns 421,924 shares of the company’s stock worth $1,295,000 after purchasing an additional 45,738 shares during the last quarter. Peapod Lane Capital LLC purchased a new stake in shares of Kyverna Therapeutics during the 1st quarter worth $765,000. TD Asset Management Inc lifted its position in shares of Kyverna Therapeutics by 179.5% during the 2nd quarter. TD Asset Management Inc now owns 252,196 shares of the company’s stock worth $774,000 after purchasing an additional 161,954 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its position in shares of Kyverna Therapeutics by 206.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 118,297 shares of the company’s stock worth $363,000 after purchasing an additional 79,695 shares during the last quarter. 18.08% of the stock is owned by hedge funds and other institutional investors.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.